

Supplementary Materials

Table S1. The clinical information of patients in different groups.

	TN1/PN1/SN1	TN0/PN0/SN0	<i>p</i>
Male/female	1/7	2/12	0.709
Age	41.625 ± 8.733	41.714 ± 11.159	0.985
Body mass index	25.691 ± 3.027	24.086 ± 2.242	0.170
Maximum diameter of tumor (cm)	2.638 ± 0.774	1.857 ± 0.712	0.026

Table S2. Altered pathways in comparisons (TN1 and PN1, TN0 and PN0) by pathway analysis and enrichment analysis.

Pathway	Total	Hits	<i>p</i>	FDR
TN1and PN1				
Pathway analysis ^a				
Pyrimidine metabolism	39	4	0.002	0.012
Histidine metabolism	16	2	0.019	0.031
Neomycin, kanamycin and gentamicin biosynthesis	2	1	0.027	0.031
Fructose and mannose metabolism	20	2	0.029	0.031
Citrate cycle (TCA cycle)	20	2	0.029	0.031
Beta-Alanine metabolism	21	2	0.031	0.031
Enrichment analysis ^b				
Fructose and Mannose Degradation	32	3	0.025	0.030
Thyroid hormone synthesis	13	2	0.027	0.030
Pyrimidine Metabolism	59	4	0.029	0.030
Beta-Alanine Metabolism	34	3	0.030	0.030
TN0 and PN0				
Pathway analysis ^a				
Citrate cycle (TCA cycle)	20	3	0.000	0.002
Glyoxylate and dicarboxylate metabolism	32	3	0.002	0.005
Pyrimidine metabolism	39	3	0.003	0.005
Beta-Alanine metabolism	21	2	0.011	0.014
Tyrosine metabolism	42	2	0.040	0.040
Enrichment analysis ^b				
Citric Acid Cycle	32	3	0.003	0.012
Thyroid hormone synthesis	13	2	0.006	0.012
Pyrimidine Metabolism	59	3	0.016	0.021
Beta-Alanine Metabolism	34	2	0.041	0.041

^a Pathway analysis of metabolic alters based on KEGG database.

^b Enrichment analysis of metabolic alters based on SMPDB.




Figure S1. Strategy for the metabolomic study regarding PTC.